Cogent Biosciences clinical trials we track

Check company identity source

Phase 3 1 trial

Phase 2 2 trials

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2026-11-30DaybezuclastinibCogent Biosciences, Inc. · COGTCompany-disclosed PDUFA goal dateAnnounced review targetGISTOpen original source
Read source excerpt

Preparing for anticipated bezuclastinib launch in GIST; PDUFA action date November 30, 2026

First seen: 07 Nov 2026 · Evidence last checked: 07 Nov 2026

2026-12-30DaybezuclastinibCogent Biosciences, Inc. · COGTCompany-disclosed PDUFA goal dateAnnounced review targetNonAdvSMOpen original source
Read source excerpt

We submitted the first NDA for bezuclastinib in patients with NonAdvSM in December 2025, which was accepted by the FDA in March 2026. The FDA assigned a Prescription Drug User Fee Act ("PDUFA") target action date of December 30, 2026.

First seen: 07 Nov 2026 · Evidence last checked: 07 Nov 2026

2026-12-30DaybezuclastinibCogent Biosciences, Inc. · COGTCompany-disclosed PDUFA goal dateAnnounced review targetNonAdvSMOpen original source
Read source excerpt

Potential FDA approval of bezuclastinib in NonAdvSM – PDUFA date of December 30, 2026

First seen: 08 Nov 2026 · Evidence last checked: 08 Nov 2026

2027-06-29DaybezuclastinibCogent Biosciences, Inc. · COGTCompany-disclosed PDUFA goal dateAnnounced review targetAdvSMOpen original source
Read source excerpt

Potential FDA approval of bezuclastinib in AdvSM – PDUFA date of June 29, 2027

First seen: 08 Nov 2026 · Evidence last checked: 08 Nov 2026

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters